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ABSTRACT 
Wilson disease (WD) is an autosomal recessive disorder that is caused by the toxic 
accumulation of copper (Cu) in the liver. The ATP7B gene, which is mutated in WD, 
encodes a multi-transmembrane domain ATPase that traffics from the trans-Golgi 
network (TGN) to the canalicular area of hepatocytes, where it facilitates excretion of 
excess Cu into the bile. Several ATP7B mutations, including H1069Q and R778L that are 
two of the most frequent variants, result in protein products, which, although still 
function remain in the endoplasmic reticulum (ER). Thus, they fail to reach Cu excretion 
sites, resulting in the toxic build-up of Cu in the liver of WD patients. Therefore, 
correcting the location of these mutants, by leading them to the appropriate functional 
sites in the cell, should restore Cu excretion and would be beneficial to help large cohorts 
of WD patients. However, molecular targets for correction of ER-retained ATP7B 
mutants remain elusive. Here we show that expression of the most frequent ATP7B 
mutant, H1069Q, activates p38 and JNK signaling pathways, which favor the rapid 
degradation of the mutant. Suppression of these pathways with RNAi or specific 
chemical inhibitors results in the substantial rescue of ATP7B
H1069Q
 (as well as that of 
several other WD-causing mutants) from the ER to the TGN compartment, in recovery of 
its Cu-dependent trafficking and in reduction of intracellular Cu levels.  
 
CONCLUSION: In summary, our findings indicate p38 and JNK as intriguing targets for 
correction of WD-causing mutants and, hence, as potential candidates, which could be 
evaluated for the development of novel therapeutic strategies to combat WD.  
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INTRODUCTION 
 
The liver is essential for the maintenance of copper (Cu) homeostasis, as it plays a central 
role in the excretion of this essential, yet toxic, metal. This is highlighted by Wilson 
disease (WD), an autosomal recessive disorder in which biliary excretion of Cu is 
severely impaired causing the toxic accumulation of the metal in the liver (1, 2).  
 
The ATP7B gene (defective in WD) encodes a Cu-transporting P-type ATPase that 
pumps cytosolic Cu across cellular membranes, using the energy derived from ATP 
hydrolysis (Fig. 1A). Increased Cu levels prompt ATP7B to traffic from the Golgi to 
compartments that are involved in Cu excretion (3, 4). WD-associated mutations affect 
the intracellular trafficking of ATP7B to the canalicular area of hepatocytes and/or the 
protein’s ability to transfer Cu across the membrane (3, 4). This results in the failure of 
hepatocytes to remove excess Cu into the bile and, thus, lead to the accumulation of the 
metal, which causes cell death and Cu accumulation in extra-hepatic tissues. Therefore, 
clinical features of WD often include hepatic abnormalities, neurological defects, and 
psychiatric symptoms. When left untreated, liver failure may result in death (1, 2). 
 
WD treatment may be successfully approached with zinc salts and Cu-chelating agents. 
However, these treatments do have serious toxicities (2, 5). Moreover, about one-third of 
WD patients do not respond efficiently either to Zn or to Cu chelators (6). All considered, 
developing novel WD treatment strategies has become an important goal. When 
approaching therapy solutions, properties of WD-causing mutants should be carefully 
considered. The most frequent ATP7B mutations (Fig. 1A), H1069Q (40%-75% in the 
white patient population) and R778L (10%-40% of Asian patients), result in ATP7B 
proteins with significant residual activities (7-9), which, however, are strongly retained in 
the endoplasmic reticulum (ER) (10). Notably, many other WD-causing ATP7B mutants 
with substantial Cu-translocating activity undergo complete or partial arrest in the ER 
(11).  Thus, although potentially able to transport Cu, these ATP7B mutants cannot reach 
the Cu excretion sites to remove excess Cu from hepatocytes. ER retention of such 
ATP7B mutants occurs due to their mis-folding (10, 11) and increased aggregation (12), 
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and hence due to their failure to fulfill the requirements of the ER quality control 
machinery. As a result, the cellular proteostatic network recognizes ATP7B mutants as 
defective and directs them towards the ER-associated protein degradation (ERAD) 
pathway (9). Therefore, identifying molecular targets for the recovery of partially- or 
fully-active ATP7B mutants from the ER to the appropriate functional compartment(s) 
would be beneficial for the majority of WD patients. 
 
Here we demonstrate, by using both systems biology and classical approaches, that the 
degradation of the most frequent ATP7B
H1069Q
 mutant is under the control of the stress 
kinases p38 and JNK. Suppressing both p38 and JNK resulted in the efficient correction 
of the mutant, thus allowing it to be transported from the ER to the TGN, and supported 
its Cu-induced trafficking to the post-Golgi vesicles and canalicular surface of polarized 
hepatic cells. As a consequence, treatments with p38 or JNK inhibitors reduced Cu 
accumulation in cells expressing ATP7B
H1069Q
 and attenuated degradation of the mutant 
due to its improved sorting from the ER into the secretory pathway. Our findings suggest 
that p38 and JNK signaling pathways may serve as attractive targets for the correction of 
WD-causing mutants and could be explored for the development of therapeutic 
approaches that counteract WD. 
 
MATERIALS AND METHODS 
 
Antibodies, reagents and DNAs 
Antibodies against phospho-p38, phospho-JNK, phospho-ERK, p38, JNK and ERK were 
Cell Signaling Technology (Beverly, MA, USA). The DNAs of ATP7A and its mutants 
were already reported (13).  DNAs of flag-tagged MKK3, 4, 6 and 7 were obtained from 
Addgene (Cambridge MA, USA). To obtain the R778L, D765N, L776V, A874V and 
L1083F mutants of ATP7B, the pEGFPC1-ATP7B construct was used as a template and 
site-direct mutagenesis was performed according to the manufacturer instructions using 
the QuickChange kit (Stratagene, La Jolla, CA, USA). Other reagents, antibodies, DNAs 
and viruses were reported before (14). 
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Cell culture 
HeLa, HepG2 cells and primary mouse hepatocytes were grown in Dulbecco’s Modified 
Eagle’s medium (DMEM) supplemented with FCS 10% (decomplemented for HepG2 
cells), L-glutamine and Penicillin/Streptomycin.  
 
Immunoprecipitation and mass spectrometry analysis 
To compare interactomes of ATP7B
H1069Q
-GFP or ATP7B
WT
-GFP, the tagged proteins 
were immunoprecipitated from cell lysates with the anti-GFP antibody. Pull downs were 
fractionated by SDS-PAGE and the protein bands were digested with trypsin. Peptide 
mixtures were analyzed by nano-chromatography tandem mass spectrometry (nanoLC–
MS/MS) on a CHIP MS Ion Trap XCT Ultra (Agilent Technologies, Palo Alto, CA, 
USA). Peptide analysis was performed using data-dependent acquisition of one MS scan 
(mass range from 400 to 2000 m/z) followed by MS/MS scans of the three most abundant 
ions in each MS scan. Raw data from nano LC–MS/MS analyses were employed to query 
a non-redundant protein database using in house MASCOT software (Matrix Science, 
Boston, USA).  
 
Microarray analysis 
To identify the effects of ATP7B
H1069Q
 expression on the transcriptome, total RNA was 
extracted from HepG2 cells (expressing either ATP7B
H1069Q
-GFP or ATP7B
WT
-GFP) and 
hybridized on Affymetrix GeneChips. All of the raw microarray data was formatted for 
‘Gene Expression Omnibus’ (GEO) to comply with Minimum Information About a 
Microarray Experiment (MIAME) and Microarray Gene Expression Database (MGED) 
group standards (GEO number GSE51818). Microarray analyses were carried out with R, 
a free software environment. Genes that passed all filtering criteria were entered into the 
DAVID Gene Functional Annotation Tool. The gene ontology options 
GOTERM_BP_ALL and GOTERM_MF_ALL were selected and a functional annotation 
chart was generated. A maximum p value of 0.05 was chosen to select only the 
significant categories. 
 
Statistical analysis 
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Data were expressed as mean values ± standard deviation. The Student t-test was used to 
compare differences between two groups by GraphPad Prism 6 software (GraphPad 
Prism Inc., San Diego, CA, USA). Statistical significant differences between them are 
indicated by the following asterisks: * p < 0.05; ** p < 0.01; and *** p < 0.001. 
 
Other methods 
Adenoviral and VSV infection, DNA transfection, RNA interference, Q-PCR, fluorescent 
microscopy, immuno-EM, ICP-MS and Western blot analysis were done as previously 
reported (14). For details see Supplementary Materials. 
 
RESULTS 
 
Expression of the ATP7B
H1069Q
 mutant induces activation of p38 and JNK 
We utilized unbiased approaches to understand which molecular pathway could be 
targeted to correct mutants causing WD. We first sought to determine how ATP7B
H1069Q
 
mutant expression affects the transcriptome of hepatic cells. The comparison of 
microarrays from ATP7B
H1069Q
- or ATP7B
WT
-expressing cells revealed 626 differently 
expressed genes (GSE51818). Gene ontology (GO) analysis of these hits indicated 
enrichment in genes that regulate cell death and response to stress (Fig. 1B; 
Supplementary table 1). Several of these genes (SQSTM1, TXNIP, IL6R, FOSL1, 
MAP2K6 and NET1) have been reported to operate in MAPK signaling pathways 
mediated by two pro-apoptotic stress kinases, p38 and JNK (15). This might be linked to 
WD pathogenesis because reactive oxygen species (ROS) accumulating in WD (3) can 
stimulate the activity of p38 and JNK (15-18). Indeed, several ROS-sensitive genes 
(SOD2, MSRA, TP53I3) were up-regulated in ATP7B
H1069Q
-expressing cells. This 
prompted us to investigate whether the activity of these kinases rises upon ATP7B
H1069Q
 
expression. Western blot analysis revealed that phosphorylated p38 and JNK increased 
significantly in cells expressing the mutant (Fig. 1C), indicating that both kinases were 
activated. In the mean time the MEK/ERK pathway of the MAPK signaling cascade was 
not activated, as the levels of phosphorylated ERK remained unaltered in mutant-
expressing cells (Fig. S1A). 
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We also compared the interactomes of ATP7B
WT
 and ATP7B
H1069Q
. Proteomics analysis 
revealed 31 ATP7B
WT
-specific and 51 ATP7B
H1069Q
-specific interactors (Supplementary 
tables 2 and 3). GO analysis indicated that specific binding partners of ATP7B
WT
 were 
enriched in “intracellular trafficking” proteins (Fig. 1D). In contrast, the ATP7B
H1069Q
 
interactome contained numerous proteins belonging to the “unfolded protein binding”, 
“proteasome” and “ubiquitination” GO categories (Fig. 1D). These differences are in line 
with an enhanced association of the mutant with the components of the ER-associated 
quality control machinery, resulting in ER retention of the mutant (9, 10). Notably, 
specific MAPK pathways, which include p38 and JNK, have recently been shown to 
affect proteostasis of proteins such as CFTR (19) and to regulate the expression of ER 
quality control/degradation genes (15). We thus examined whether the activation of p38 
and JNK might lead to the accelerated degradation of ATP7B
H1069Q
. Indeed, 
overexpression of the upstream activators of p38 (MKK3 and MKK6) or JNK (MKK4 
and MKK7) reduced ATP7B
H1069Q
 levels, indicating increased mutant degradation (Fig. 
1E).  
 
On the whole, the above observations indicate that induction of p38 and JNK may be 
triggered by ATP7B
H1069Q
 expression. This activation, in turn, may promote ER retention 
and degradation of the mutant, increase in ROS levels (due to Cu accumulation) and 
further perturbation of ER proteostasis, generating a vicious circle (Fig. 1F). In this 
context, p38 and JNK represent regulatory centerpieces and potential druggable targets to 
prevent ER retention of the mutant and, hence, to rescue its localization and function.  
 
Suppression of p38 and JNK rescues appropriate localization and trafficking of the 
ATP7B
H1069Q
 mutant 
To test whether deactivating p38 and JNK pathways facilitates ATP7B
H1069Q
 export from 
the ER, we suppressed the activity of p38 and JNK first by using specific chemical 
inhibitors, SB202190 (SB90) and SP600125 (SP125), and then by RNAi. We initially 
evaluated the impact of p38/JNK-specific inhibitors and siRNAs in HeLa cells, given that 
the silencing of the genes of interest can be easily achieved in this cell type. In cells 
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treated with Cu chelator BCS, ATP7B
WT
 was mainly detected over the Golgi membranes, 
while ATP7B
H1069Q
 remained in the ER (Fig. 2A, upper row). Both p38 and JNK 
inhibitors (added for 24h) did not affect ATP7B
WT
 (Fig. S2A) but reduced ATP7B
H1069Q
 
within the ER and improved the delivery of the mutant to the Golgi (Fig. 2A, upper row; 
Fig. 2B). The correction of ATP7B
H1069Q
 localization was remarkably effective even at 
quite low concentrations (Fig. S2B). Interestingly, the combination of p38 and JNK 
inhibitors did not further increase mutant relocation from the ER to the Golgi (Fig. S3), 
suggesting that both inhibitors target similar molecular pathways for correction of 
ATP7B
H1069Q
. In control experiments the ERK inhibitor failed to correct the mutant from 
the ER to the Golgi (Fig. S1B). This indicates that only p38 and JNK branches of the 
MAPK signaling cascade are involved in mutant retention in the ER. Importantly, acute 
suppression of p38 and JNK did not impact ER export of ATP7B
H1069Q
 (Fig. S4). 
Therefore, inhibitors apparently act through the transcriptional regulation of quality 
control and/or trafficking genes rather than by reducing the direct phosphorylation of the 
mutant or components of its trafficking machinery.  
 
Next, we investigated whether the inhibitors rescue Cu-responsive trafficking of 
ATP7B
H1069Q
. CuSO4 addition induced redistribution of ATP7B
WT
 from the TGN to the 
plasma membrane (PM) and peripheral vesicular structures but failed to induce 
ATP7B
H1069Q
 relocation from the ER (Fig. 2A, lower row). Instead, when corrected by 
p38/JNK antagonists, ATP7B
H1069Q
 efficiently moved from the Golgi to the PM and 
vesicles in response to elevated Cu (Fig. 2A, C).   
 
The above results were confirmed by biochemistry and electron microscopy (EM). 
Western blot exhibited reduced amounts of ATP7B
H1069Q
 in the PM subcellular fractions 
in comparison to ATP7B
WT
, while both p38 and JNK inhibitors significantly increased 
quantities of the mutant delivered to the cell surface (Fig. S5). In turn, EM revealed 
ATP7B
H1069Q
 mainly over the ER membrane profiles, while cells incubated with p38 
antagonists contained the mutant in TGN membranes (Fig. 2D). In response to CuSO4 
treatment inhibitor-treated cells delivered ATP7B
H1069Q
 from the TGN to the cell surface 
and endosome/lysosome-like “vesicles” (Fig. 2D), which normally receive ATP7B
WT
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upon Cu overload (14). Thus, it turns out that, once corrected to the Golgi by p38/JNK 
inhibitors, the mutant reacts to increasing Cu by trafficking to Cu excretion sites, just as 
ATP7B
WT
 does. 
 
To further verify the above conclusions, we silenced different isoforms of p38 
(MAPK11-MAPK14) and JNK (MAPK8-MAPK10) in cells expressing ATP7B
H1069Q
 
(Fig. 3A). Both reduction in ER retention and recovery of Golgi and vesicle targeting of 
the mutant were detected after depletion of MAPK8, MAPK11 and MAPK14 (Fig. 3B, 
C). In addition, we sought to suppress MAP3K11, the upstream activator of both p38 and 
JNK (20), to evaluate whether this treatment improved ATP7B
H1069Q
 recovery from the 
ER. MAP3K11 has been reported to effectively correct ∆508-CFTR (19). Indeed, 
depletion of MAP3K11 resulted in the strong reduction of ATP7B
H1069Q
 in the ER (Fig. 
3B, C). 
 
We next investigated whether inhibitors of p38 or JNK overcome the ER retention of 
other ATP7B mutants with residual activity (7, 11).  Correction was achieved for D765N, 
L776V and R778L mutants, but not for A874V and L1083F variants (Fig. 4). Meanwhile, 
p38 and JNK antagonists failed to correct ATP7A mutants with post-Golgi trafficking 
defects (Fig. 5) indicating that inhibitors act mainly at the ER level. In summary, our 
observations suggest that suppressing p38 or JNK allows various ATP7B mutants to 
escape ER retention in a manner that depends on the type of mutation. 
 
p38 and JNK inhibitors rescue ATP7B
H1069Q
 trafficking and targeting in hepatic 
cells 
As a further step, we tested whether suppressing p38 and JNK is efficient in rescuing the 
mutant in WD-relevant cellular systems such as HepG2 cells and primary hepatocytes 
(21). In HepG2 cells, ATP7B
WT
 moved from the Golgi to the vesicles and cell membrane 
in response to Cu (Fig. 6A), while most of the ATP7B
H1069Q
 was arrested in the ER, 
regardless of changes in Cu concentrations (Fig. 6A). However, incubation with either 
p38 or JNK inhibitors allowed significant amounts of ATP7B
H1069Q
 to reach the Golgi 
and to be transported towards the PM and associated vesicles in response to Cu overload 
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(Fig. 6A, B). Moreover, the ATP7B
H1069Q
 mutant was targeted to the appropriate 
canalicular surface domain in polarized HepG2 cells (Fig. S6). Importantly, primary 
hepatocytes exhibited a similar response to either p38 or JNK inhibitors, which rescued 
ATP7B
H1069Q
 from the ER, and allowed it to traffic towards Golgi and post-Golgi Cu 
excretion sites (Fig. 6C, D). Therefore, hepatic cells tend to deliver the ATP7B mutant to 
the right compartments upon suppression of p38 and JNK signaling pathways.  
 
Correction of the ATP7B
H1069Q
 mutant with p38 or JNK inhibitors facilitates Cu 
excretion 
We reasoned that correcting ATP7B
H1069Q
 from the ER to the appropriate Cu excretion 
sites should reduce the total amount of intracellular Cu. To test this hypothesis we 
utilized inductively coupled plasma mass spectrometry (ICP-MS). ICP-MS 
measurements revealed higher concentrations of the metal in the cells expressing 
ATP7B
H1069Q
, while treatment with p38 or JNK inhibitor significantly reduced 
intracellular Cu levels (Fig. 7A). 
 
To further support these findings, we utilized Coppersensor 3 (CS3), which becomes 
fluorescent in the presence of bioavailable Cu (22). We found low CS3 signal in cells 
expressing ATP7B
WT
, whereas CS3 fluorescence was higher in mutant-expressing cells 
(Fig. 7B). p38 or JNK inhibitors significantly decreased CS3 signal in cells expressing 
ATP7B
H1069Q
 (Fig. 7B, C). More importantly, reduction in CS3 fluorescence (and hence 
in Cu levels) correlated to the amount of ATP7B
H1069Q
 expressed in inhibitor-treated cells 
(Fig. S7). Collectively, the above findings indicate that correcting the mutant to the 
appropriate compartments with p38/JNK antagonists allows the cells to eliminate excess 
Cu.  
 
p38 and JNK inhibitors reduce degradation of ATP7B
H1069Q
 by improving mutant 
sorting into the secretory pathway 
In the ER the failure of mis-folded protein to pass the quality control check directs such 
protein to degradation (23). Therefore, we analyzed whether p38 or JNK inhibitors 
counteract ATP7B
H1069Q
 degradation. We found that the ATP7B
H1069Q
 protein product 
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increased in response to p38 and MAPK inhibition (Fig. 8A), while the levels of its 
mRNA remained the same in treated cells (not shown). This indicated that suppressing 
p38 and JNK attenuates degradation of the mutant. To support this conclusion we treated 
cells with cycloheximide and found that p38 and JNK inhibitors significantly slowed 
down the kinetics of mutant turnover (Fig. 8B, C). Thus, our results suggest that 
suppression of p38 and JNK pathways allows ATP7B
H1069Q
 to circumvent ER-associated 
degradation. 
 
How do p38 and JNK antagonists suppress ATP7B
H1069Q
 degradation? The first 
possibility is that they directly inhibit the ERAD components that comprise the 
proteasome (23). Being protected from ERAD, aberrant ATP7B molecules would reside 
in the ER longer and, therefore, may have a higher chance to be incorporated into carriers 
that transport them from the ER to the Golgi. To test whether this is the case, we treated 
ATP7B
H1069Q
-expressing cells with proteasome inhibitor MG132. MG132 increased 
ATP7B
H1069Q
 levels (Fig. 8D) but failed to overcome mutant retention in the ER (Fig. 
8E). This indicates that inhibitor-mediated recovery of ATP7B
H1069Q
 from the ER does 
not involve ERAD components.  
 
Therefore, ATP7B
H1069Q
 may be protected from the degradation as a result of accelerated 
trafficking from the ER. To verify this we first observed whether p38 and JNK inhibitors 
accelerated overall trafficking rates in the secretory pathway. This was not the case as 
trafficking kinetics of generic cargo protein VSVG was not altered in SB90- or SP125- 
treated cells (Fig. S8).  
 
We further hypothesized that the suppression of p38 and JNK might specifically 
accelerate trafficking rates of the ATP7B
H1069Q
 mutant from the ER to the Golgi. To test 
this hypothesis we used a selective photo-bleaching, which allows to analyze protein 
exchange between different compartments in live cells (24). We bleached ATP7B
WT
-GFP 
or ATP7B
H1069Q
-GFP in the Golgi region and observed how the material from the ER 
recovered GFP signal in the bleached area (Fig. 8F). Recovery of ATP7B
H1069Q
-GFP 
fluorescence in the Golgi reached the plateau with the same dynamics (t1/2≈1 min) both in 
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control and inhibitor-treated cells (Fig. 8G). However, the amount of ATP7B
H1069Q
-GFP 
that reappeared within the Golgi over the same time interval was markedly higher in cells 
incubated with p38 or JNK inhibitors (Fig. 8F, G). These observations indicate that 
suppressing p38 and JNK does not shorten the time needed for a given ATP7B
H1069Q
 
molecule to be transported from the ER to the Golgi. Instead, p38 and JNK antagonists 
allow a higher number of ATP7B
H1069Q
 molecules to be sorted from the ER and 
transported to the Golgi during this interval.  
 
To further support this point we evaluated the distribution of ATP7B
H1069Q
 at the ER 
export sites (ERES) using immuno-EM. ERES contains coated buds (Fig. 8H-J, 
arrowheads) emerging from the ER cisternae and associated vesicular-tubular membranes 
(Fig. 8H-J, empty arrows) that carry newly synthetized proteins to the Golgi. Normally, 
membrane proteins directed into the secretory pathway (like ATP7B
WT
) undergo 
enrichment in the ERES membranes (Fig. 8H, empty arrows) over regular ER cisternae 
(25). Such concentration in ERES was not detected for ATP7B
H1069Q
. Indeed, 
ATP7B
H1069Q
–associated gold particles decorated mainly ER cisternae (Fig. 8I, arrows) 
and were scarce in the coated buds (Fig. 8I, arrowhead) and neighboring vesicles (Fig. 8I, 
empty arrows). Incubation with either p38 or JNK inhibitor increased the density of 
ATP7B
H1069Q
 in the ERES buds (Fig. 8J, arrowhead) and vesicular profiles (Fig. 8J, 
empty arrows) and reduced ATP7B
H1069Q
 signal in ER cisternae (Fig. 8J, arrows; 
quantification in Fig. 8H). This trend indicates that inhibiting p38 and JNK facilitates 
sorting of ATP7B
H1069Q
 from the ER into nascent Golgi-directed transport intermediates.  
 
DISCUSSION 
 
The main finding in this study is that p38 and JNK kinases play an important role in WD 
by promoting retention and degradation of the ATP7B
H1069Q
 mutant in the ER. Thus, 
suppression of p38 and JNK allows ATP7B
H1069Q
 to reach the post-Golgi vesicles and the 
apical surface in hepatocytes, from where it can contribute to the removal of excess Cu 
from the cell. As a consequence, treatments with p38 or JNK inhibitors reduce Cu 
accumulation in cells expressing ATP7B
H1069Q
. Thus, p38 and JNK represent attractive 
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targets for correction of the ATP7B mutant localization and function and could be 
considered for the development of novel therapeutic strategies to counteract WD. 
 
A large proportion of WD-causing ATP7B mutations result in a protein product that is 
still able to pump Cu, but remains retained within the ER, and undergoes accelerated 
degradation. Therefore, a therapeutic strategy that can target the proteostasis of these 
ATP7B mutants to reduce their degradation and to improve their folding and export 
would be beneficial for the large cohort of WD patients. 
 
In recent years, several attempts have been made in this direction, with the use of 
correctors such as curcumin and phenylbutyrate (9). The rationale for using these drugs is 
that they are effective in rescuing misfolded CFTR or lysosomal enzymes (26, 27), which 
result in cystic fibrosis and lysosomal storage diseases, respectively. These drugs were 
shown to reduce the degradation of several ER-retained mutants of ATP7B (9). Whether 
and how these correctors rescue the appropriate localization of these ATP7B mutants 
and, therefore, recover the ability of these aberrant ATP7B proteins to eliminate Cu 
remains to be demonstrated.  
 
Several proteins have also been reported to modulate the degradation of the ATP7B 
mutants and/or their retention in the ER. These include COMMD1 (28), clusterin (29) 
and CRYAB (12). However, these proteins do not belong to the “druggable” category, 
and, thus, their potential for the development of drugs to cure WD remains questionable. 
Instead, both p38 and JNK represent bona-fide druggable targets and their inhibitors 
show high efficiency in rescuing several of these pathogenic ATP7B variants. Their 
ability to recover ATP7B
H1069Q 
trafficking in primary hepatocytes indicates potential 
efficacy in the hepatic tissue. This property of p38 and JNK inhibitors is really important 
for therapy since the number of active compounds, which are effective in immortalized 
cell lines, frequently fail to provide the same beneficial impact in primary cells or 
animals (30). Unfortunately an animal model that recapitulates ATP7B
H1069Q 
mutation 
remains to be developed. Therefore, evaluation of the inhibitor efficiency in vivo 
represents a further challenging and important goal. 
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Of note, the therapeutic potential of some p38 and JNK antagonists has been explored for 
the treatment of different disorders. Some p38 and JNK inhibitors have entered phase 2 
clinical studies for other disorders (ClinicalTrials.gov identifiers: NCT00316771, 
NCT00303563, NCT00383188, NCT00620685, NCT00395577, NCT00205478, 
NCT00390845, NCT00570752, NCT01630252) (31). Thus, in theory the passage of such 
p38 and JNK inhibitors into clinical use for WD might be rapid, as their toxicity level has 
reported to be relatively low (32) and may be further decreased through specific delivery 
using ligands of the asialoglycoprotein receptor (33).  
 
Which molecular mechanisms operate behind the correction of the ATP7B
H1069Q
 mutant? 
As we have demonstrated, the inhibition of p38 and JNK manifests two main phenomena: 
a reduction in ATP7B
H1069Q
 degradation and an improved ATP7B
H1069Q
 delivery to the 
Golgi apparatus and to the post-Golgi compartments. It turns out that a reduction in the 
degradation of ATP7B
H1069Q
 occurs as a consequence of increasingly efficient sorting of 
ATP7B
H1069Q
 into the secretory pathway. Indeed, photo-bleaching experiments and 
immuno-EM indicate that p38 and JNK inhibitors facilitate ATP7B mutant sorting from 
the ER into the secretory pathway at the level of the ER exit sites, while overall 
membrane trafficking rates remain unchanged. 
 
Therefore, corrections of ATP7B
H1069Q
 from the ER into the secretory route probably 
arise through the modulation of the proteostatic network, which improve the ability of 
ATP7B
H1069Q
 to be captured by the export machinery in inhibitor-treated cells. 
ATP7B
H1069Q
 interactome exhibits a significant enrichment in components of ER quality 
control and ERAD. Thus, an excessive amount of quality control proteins that bind the 
mutant may prevent its transition from the ER to the secretory pathway. Such chaperone-
mediated ER trap was reported for CFTR mutant (34). The inhibitors of p38 and JNK 
might reduce the amounts of quality control proteins that bind the ATP7B mutant and in 
this way allow ATP7B
H1069Q
 to escape into the secretory pathway.  
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Alternatively, the inhibition of p38 and JNK may result in the up-regulation of some 
chaperones that are negatively regulated by these stress kinases. Thus, up-regulation of 
such chaperones could improve mutant folding and stability in cells treated with p38 or 
JNK antagonists. We have previously shown that CRYAB chaperone significantly 
facilitates ATP7B
H1069Q
 exit from the ER (12). Its activity and expression appear to be 
regulated by p38 (35), and, therefore, might also be modulated by p38 inhibition. It 
remains to be investigated whether p38 antagonists can induce CRYAB up-regulation in 
hepatocytes that express ATP7B mutants. 
 
Although p38 and JNK inhibitors were effective in correcting several ER-retained 
ATP7B variants, they did not rescue a few other ATP7B mutants from the ER. 
Interestingly, mutations in the same domain (like ATP7B
H1069Q
 and ATP7B
L1083F
) are 
differently sensitive to p38 and JNK inhibitors. This indicates that p38-dependent and 
JNK-dependent machineries have a certain level of specificity and that inhibiting them 
does not seem to threaten the global quality-control processes at the level of the ER. On 
the other hand, p38 and JNK inhibitors also rescue some, but not all, ER-retained mutants 
of other membrane proteins, such as CFTR and P-glycoprotein (19). Therefore, these p38 
and JNK inhibitors might modulate specific mechanisms involved in the recognition of 
common (or similar) protein-folding defects.  
 
In conclusion, p38 and JNK signaling pathways may serve as attractive targets to 
counteract WD by rescuing ER-retained ATP7B mutants. It remains to be established to 
what extent suppression of these pathways would be able to prevent toxic copper 
accumulation in model animals or patients carrying corresponding ATP7B mutations. On 
the other hand, the impact of p38 and JNK antagonists on the key components of 
proteostatic networks requires further detailed investigation. This may expand the use of 
kinase inhibitors to correction of other ER-retained pathogenic mutants and, hence, to 
open new avenues for therapeutic strategies to combat disorders that are caused by 
protein misfolding. 
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FIGURE LEGENDS 
Fig. 1. Expression of the ATP7B
H1069Q
 mutant is associated with activation of p38 
and JNK signaling pathways. 
(A) Schematic structure of ATP7B. Black balls show N-terminal metal binding domains. 
Numbers indicate trans-membrane helices. The domains, which regulate ATPase activity, 
are indicated in italic with D residue for catalytic phosphorylation. Yellow stars indicate 
the position of the most frequent WD-causing mutations, H1069Q and R778L. (B) 
HepG2 cells were infected with Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP and 
prepared for microarray analysis (see Methods). Genes that were differently expressed in 
cells expressing ATP7B
H1069Q
 were analyzed for gene ontology (GO) enrichment. The pie 
diagram shows the GO categories that were enriched among the altered genes in 
ATP7B
H1069Q
-expressing cells, as opposed to cells expressing ATP7B
WT 
(see also 
Supplementary table 1). Genes involved in the regulation of apoptosis constituted the 
largest group of genes, whose expression was altered by the ATP7B
H1069Q
 mutant. (C) 
HepG2 cells were infected with Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP and 
analyzed with western blot. Phosphorylated forms of p38 (P-38) or JNK (P-JNK) 
increased in cells expressing the ATP7B
H1069Q
 mutant, while overall amounts of p38 or 
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JNK remained similar in WT- and mutant-expressing cells. (D) Putative interactors of 
ATP7B
WT
 and ATP7B
H1069Q
 were identified using a proteomics approach (see Methods). 
The diagram shows the number of interactors that were specific for ATP7B
WT
 or for 
ATP7B
H1069Q
, as well as the number of common interactors. GO analysis revealed 
ATP7B
WT
 interactors to be enriched in proteins belonging to membrane trafficking 
categories, while mutant-specific interactors were enriched in proteins involved in ER-
associated protein quality control and degradation. (E) HepG2 cells expressing 
ATP7B
H1069Q
 were transfected with activators of p38 (MKK3 and MKK6) or JNK 
(MKK4 and MKK7). Western blot (see also quantification graph) revealed a decrease in 
ATP7B
H1069Q
 levels in cells expressing p38 or JNK activators. Na/K-ATPase was used as 
input control. The modest decrease in ATP7B
H1069Q
 in cells transfected with MKK4 is due 
to lower over-expression of MKK4 in comparison to other MKKs. (F) The schematic 
drawing shows a vicious circle that is generated by expression of the ATP7B
H1069Q
 
mutant, which leads to activation of ER quality control and degradation of ATP7B
H1069Q
.  
Аs a consequence of ATP7B
H1069Q
 loss, ROS increase and stimulates p38 and JNK 
signaling which triggers further retention and degradation of the mutant in the ER 
preventing it from being exported to the secretory pathway.  
 
Fig. 2. Inhibitors of p38 and JNK correct localization and trafficking of 
ATP7B
H1069Q
 mutant. 
(A) HeLa cells were infected with Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP, 
incubated overnight with 200 µM BCS, and fixed or incubated for an additional 2h with 
100 µM CuSO4. In response to Cu, ATP7B
WT
 (left column) traffics from the Golgi 
(arrowheads in upper panel) to the PM and vesicle (arrows in lower panel), while 
ATP7B
H1069Q
 (second column) is retained within the ER under both low and high Cu 
conditions. p38 inhibitor SB202190 (5mM) or JNK inhibitor SP600125 (2mM) were 
added to the cells 24h before fixation (as indicated in the corresponding panels). Fixed 
cells were further labeled for TGN46 and visualized under a confocal microscope. Both 
p38 and JNK inhibitors corrected ATP7B
H1069Q
 from the ER to the Golgi (arrowheads in 
upper panels) under low Cu conditions and to the PM and vesicles (arrows in lower 
panels) in high Cu conditions. (B) Cells were treated with BCS and drugs as shown in 
panel A. Fluorescence of ATP7B signal in the Golgi (average ± SD, n=40 cells) was 
quantified and normalized to total cell fluorescence. Both inhibitors caused an increase of 
ATP7B
H1069Q
 signal in the Golgi region. (C) Cells were treated as in panel A. The 
percentage of cells (average ± SD, n=10 fields) with an ATP7B signal in the ER, Golgi or 
PM/vesicles was calculated. Both p38 and JNK inhibitors reduced the percentage of cells 
exhibiting ATP7B
H1069Q
 in the ER and increased the number of cells in which ATP7B 
was corrected to the Golgi under low Cu conditions and to the PM and vesicles upon Cu 
stimulation. (D) Cells were treated as in panel A and prepared for immuno-EM (see 
Methods). Arrows indicate ATP7B
H1069Q
 in the ER. Arrowheads show ATP7B
WT
 or 
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ATP7B
H1069Q
 in the Golgi. Empty arrows indicate ATP7B
WT
 or ATP7B
H1069Q
 signal at 
the PM, while asterisks label ATP7B-positive MVB-like vesicles. Scale bar: 5 µm (A), 
260 nm (D). 
 
Fig. 3. Silencing of several p38 and JNK isoforms corrects localization and 
trafficking of the ATP7B
H1069Q
 mutant.  
(A) HeLa cells were incubated with siRNA, which targets specific genes (indicated in 
graph) belonging to the p38 and JNK pathways. The efficiency of silencing for each gene 
was evaluated by quantitative RT-PCR and expressed as fold-change (average ± SD; n=3 
experiments) after normalization to mRNA levels of the same gene in control cells 
(treated with scramble siRNA). (B) HeLa cells were silenced for different p38 and JNK 
isoforms as in panel A, then infected with Ad-ATP7B
H1069Q
-GFP and incubated for 2h 
with 100 µM CuSO
4
. Fixed cells were then labeled for TGN46 and visualized under a 
confocal microscope. Silencing of MAPK8, MAPK11, MAPK14 or MAP3K11 showed 
the rescue of ATP7B
H1069Q
 from the ER and its movement to the post-Golgi vesicles 
(arrows) and PM. (C) Cells were treated as in panel B. The percentage of cells (average ± 
SD, n=10 fields) with ATP7B
H1069Q
 signal in the ER was calculated. RNAi of MAPK8, 
MAPK11, MAPK14 and MAP3K11 reduced the percentage of cells exhibiting 
ATP7B
H1069Q
 in the ER. Scale bar: 4.7 µm (B). 
 
Fig. 4. Impact of p38 and JNK inhibitors on localization of ER-retained ATP7B 
mutants. 
(A) HeLa cells were transfected with different ATP7B mutants (indicated in each panel), 
then treated for 24h with either p38 or JNK inhibitors and exposed to 100 µM CuSO
4
 for 
2h. Cells were then fixed, labeled for TGN46 and visualized under a confocal 
microscope. All mutants exhibited clear ER patterns in cells that were not treated with 
inhibitors. Incubation with either p38 or JNK inhibitors allowed R778L, D765N and 
L776V mutants of ATP7B to be transported to the Golgi, post-Golgi vesicles (arrows) and 
PM. In contrast, inhibitors did not recover either L1083F or A874V mutants of ATP7B 
from the ER (two bottom rows). (B) Cells were treated as in panel A. The percentage of 
cells (average ± SD, n=10 fields) with ATP7B signal in the ER was calculated for each 
mutant. p38 and JNK inhibitors reduced the percentage of cells that exhibited R778L, 
D765N and L776V in the ER. Scale bar: 5 µm (А). 
 
Fig. 5. p38 and JNK inhibitors do not rescue post-Golgi trafficking of ATP7A 
mutants. 
HeLa cells were transfected with either ATP7A
WT
 (A), ATP7A
A1362D
 (B) or ATP7A
L873R
 
(C) mutant.  Then the cells were exposed to a 200 µM treatment with BCS (-Cu) and 
fixed directly or incubated with 100 µM CuSO4 for an additional 2h (+Cu). p38 or JNK 
inhibitors were added (as indicated in panels B and C) for 24h prior to fixation. Fixed 
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cells were labeled for TGN46 and visualized under a confocal microscope. (A) ATP7A
WT
 
moved from the Golgi (top panel) to the PM (bottom panel) after Cu increase. (B) 
ATP7B
A1362D
 mutant remained associated with TGN46 under both low and high Cu 
conditions (left column). Neither p38 nor JNK inhibitors allowed the mutant to be 
transported from the Golgi to the PM in response to increasing Cu (middle and right 
column). (C) The ATP7A
L873R
 mutant remained distributed over the PM, independently 
of the Cu levels (left column). Incubation with p38 or JNK inhibitors did not correct the 
mutant from the PM to the Golgi (middle and right column), even when Cu levels were 
low (top row). Scale bar: 4.8 µm (A-C). 
 
Fig. 6. Suppression of p38 and JNK corrects localization and trafficking of 
ATP7B
H1069Q
 mutant in hepatic cells. 
(A) HepG2 cells were infected with Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP, 
incubated overnight with 200 µM BCS, and fixed or incubated for an additional 2h with 
100 µM CuSO
4
. In response to Cu, ATP7B
WT
 (left column) traffics from the Golgi 
(arrowheads in upper panels) to the PM and vesicles (arrows in lower panels), while 
ATP7B
H1069Q
 (second column) is retained in the ER under both low and high Cu 
conditions. p38 or JNK inhibitors were added to the cells 24h before fixation (as 
indicated in the corresponding panels). Fixed cells were then labeled for TGN46 and 
visualized under a confocal microscope. Both p38 and JNK inhibitors corrected 
ATP7B
H1069Q
 from the ER to the Golgi (arrowheads in upper panels) under low Cu 
conditions and to the PM and vesicles  (arrows in lower panels) upon Cu exposure. (B) 
Cells were treated as in panel A. The percentage of cells (average ± SD, n=10 fields) with 
ATP7B signal in the ER, Golgi or PM/vesicles was calculated. Both p38 and JNK 
inhibitors reduced the percentage of cells exhibiting ATP7B
H1069Q
 in the ER 
independently from the Cu levels and increased the number of cells in which ATP7B was 
corrected to the Golgi under low Cu conditions and to the PM and vesicles upon Cu 
stimulation. (C) Primary hepatocytes isolated from mice liver cells were infected with 
Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP, and then incubated with 100 µM CuSO
4
 for 
2h. p38 or JNK inhibitors were added to the cells 24h before fixation (as indicated in the 
corresponding panels). Fixed cells were then labeled for giantin and visualized under a 
confocal microscope. Both p38 and JNK inhibitors corrected ATP7B
H1069Q
 from the ER to 
the PM and vesicles (arrows). (D) Primary hepatocytes were treated as in panel C. The 
percentage of cells (average ± SD, n=10 fields) with ATP7B signal in the ER, Golgi or 
PM/vesicles was calculated. Both p38 and JNK inhibitors reduced the percentage of cells 
exhibiting ATP7B
H1069Q
 in the ER and increased the number of cells in which ATP7B was 
corrected to the PM and vesicles upon Cu stimulation. Scale bar: 5 µm (A), 5.3 µm (C). 
 
 Fig. 7. Inhibitors of p38 and JNK reduce copper levels in cells expressing 
ATP7B
H1069Q
 mutant. 
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(A) HepG2 cells were infected with Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP and 
incubated with p38 or JNK inhibitor. CuSO4 at 100 µM concentration was added to the 
cells for the last 2h of incubation with the inhibitors. The cells were examined with ICP-
MS (see Methods), which revealed an increase in normalized intracellular Cu levels 
(average ± SD; n=3 experiments) in ATP7B
H1069Q
-expressing cells. Both p38 and JNK 
inhibitors reduced Cu levels in ATP7B
H1069Q
-expressing cells. (B) HepG2 cells were 
infected with Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP and incubated for 2h with 100 
µM CuSO4 and loaded with CS3 before fixation. p38 or JNK inhibitors were added to the 
cells 24h before fixation (as indicated in the corresponding panels). Confocal microscopy 
images show CS3 fluorescence in red (top row), in white (middle row) and in false color 
scale (bottom row). Cells expressing ATP7B
H1069Q
 exhibited higher CS3 signals than cells 
expressing ATP7B
WT
, while both p38 and JNK inhibitors decreased CS3 fluorescence in 
ATP7B
H1069Q
-expressing cells. (C) Quantification revealed an increase in CS3 
fluorescence (average ± SD; n=10 fields) in cells expressing ATP7B
H1069Q
 and a decrease 
of CS3 signal upon incubation with either p38 or JNK inhibitors. Scale bar: 14 µm (C).  
 
Fig. 8. p38 and JNK inhibitors reduce degradation of ATP7B
H1069Q
 mutant and 
improve its sorting into the secretory pathway.  
 (A) HepG2 cells were infected with Ad-ATP7B
H1069Q
 and treated with p38 or JNK 
inhibitor. Western blot revealed an increase in the amount of ATP7B
H1069Q
 after 
suppression of p38 or JNK. (B, C) HepG2 cells expressing ATP7B
H1069Q
 were treated 
with p38 and JNK inhibitors and then exposed to 100µM cycloheximide (CHX) for 
different time intervals. Western blot (B) and quantification of ATP7B
H1069Q
 bands (C) 
showed a decrease of ATP7B
H1069Q
 signals (means±SD; n=3 experiments) in control cells 
exposed to CHX, while p38 and JNK inhibitors attenuated the decay of ATP7B
H1069Q
 
levels. (D, E) HepG2 cells expressing ATP7B
H1069Q
 were treated with 20µM proteasome 
inhibitor MG132. Although Western blot indicated an increase in ATP7B
H1069Q
 protein 
levels (D), the localization of the mutant (E) was similar in control and MG132-treated 
cells. (F, G) HeLa cells expressing either ATP7B
WT
-GFP or ATP7B
H1069Q
-GFP were 
observed in vivo. p38 or JNK inhibitor was added to some ATP7B
H1069Q
-GFP-expressing 
cells 24h before the experiment. The GFP signal within the Golgi area (outlined in red) 
was photo-bleached (see Methods), and the kinetics of its recovery in the bleached region 
was analyzed. Both time-lapse images (F) and a kinetics plot (G) revealed more efficient 
recovery of ATP7B
WT
-GFP in comparison to the mutant. Incubation with p38 or JNK 
inhibitor led to recovery of higher ATP7B
H1069Q
-GFP levels (means±SD; n=6 cells) in the 
bleached Golgi area (F, G), although the half time (t1/2) of the recovery process remained 
similar in control and treated cells (G). (H-K) HepG2 cells expressing ATP7B
WT
-GFP or 
ATP7B
H1069Q
-GFP were fixed and prepared for immuno-EM with anti-GFP antibody. Part 
of ATP7B
H1069Q
-GFP-expressing cells was incubated with p38 or JNK inhibitor. ER 
(arrows), buds (arrowheads) or ERES vesicular/tubular profiles (empty arrows) are 
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indicated in panels H-J. Panel K shows an increase in normalized density of gold 
particles associated with ATP7B
H1069Q
-GFP (means±SD; n=20 ERES) at the ERES 
structures in inhibitor-treated cells. Scale bar: 6.5 µm (E), 5 µm (F), 180 nm (H-J).  
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SUPPLEMENTARY FIGURE LEGENDS 
 
Sup. Fig. 1. ER retention of ATP7B
H1069Q
 mutant does not require activation of 
MEK/ERK signaling pathway.  
(A) HepG2 cells were infected with Ad-ATP7B
WT
-GFP or Ad-ATP7B
H1069Q
-GFP and 
prepared western blot to reveal levels of phosphorylated and total ERK (p-ERK and ERK 
respectively). Both p-ERK and ERK levels did not exhibit significant changes in cells 
expressing ATP7BH1069Q mutant. (B) HepG2 cells were infected withAd-ATP7B
H1069Q
-
GFP and incubated for 2h with BCS. Specific inhibitors of MEK/ERK, PD318088 (5µM) 
or GSK1120212 (5µM), were added to the cells 24h before fixation (as indicated in 
corresponding panels). Fixed cells were than labeled for TGN46 and visualized under 
confocal microscope. Treatment with each inhibitor did not recover ATP7B
H1069Q
 from 
the ER to the TGN. Scale bar: 5µm (B). 
 
 
Sup. Fig. 2. Characterization of the impact of p38 and JNK inhibitors on trafficking 
of ATP7B and its mutant.  
(A) Hela cells were infected with Ad-ATP7BWT-GFP incubated overnight exposure to 
200 μM BCS and fixed or incubated for additional 2h with 100 μM CuSO4 (as indicated 
on panels). ATP7BWT moves from the Golgi (arrowheads) to PM and vesicles (arrows) in 
response to CuSO4. p38 inhibitor SB202190 (5µM) or JNK inhibitor SP600125 (2µM) 
were added to the cells 24h before fixation (as indicated in corresponding panels). Both 
inhibitors did not affect ability of ATP7BWT to traffic from the Golgi to PM and vesicles 
(arrows in bottom row) in response to increased Cu. (B) Hela cells were infected with 
Ad-ATP7BH1069Q-GFP fo 2h with 100 μM CuSO4 (as indicated on panels). p38 inhibitor 
SB202190 or JNK inhibitor SP600125 were added to the cells 24h before fixation at 
different concentrations. Then the cells were stained for TGN46 and analyzed under 
confocal microscope. Percentage of the cells (average ± SD, n=10 fields) with ATP7B 
signal in the ER was calculated. Both p38 and JNK inhibitors reduced percentage of the 
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2 
cells that exhibit ATP7BH1069Q in the ER in concentration-dependent manner. Scale bar: 5 
μm (A). 
 
Sup. Fig. 3. p38 inhibitor, JNK inhibitor or their mixture correct ATP7BH1069Q 
localization with similar strength. 
(A) HeLa cells were infected with Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP, 
incubated for 2h with 200 μM BCS and fixed. p38 inhibitor SB202190 (5μM) or JNK 
inhibitor SP600125 (2μM) or mixture of both inhibitors were added to the cells 24h 
before fixation (as indicated in corresponding panels). Fixed cells were than labeled for 
TGN46 and visualized under confocal microscope. p38 and JNK inhibitors as well as 
their mixture corrected ATP7BH1069Q from the ER to the Golgi with similar amplitude. 
(B) Fluorescence of ATP7B signal in the Golgi (average ± SD, n=40 cells) was 
quantified and normalized to total cell fluorescence. p38 and JNK inhibitors (or their 
mixture) caused increase of ATP7BH1069Q signal in the Golgi region. Exposure of the 
cells to the mixture of inhibitors does not significantly increase ATP7BH1069Q signal in the 
Golgi when compared to each inhibitor alone. (C) The percentage of the cells (average ± 
SD, n=10 fields) with an ATP7B signal in the ER, or Golgi was calculated. p38 and JNK 
inhibitors alone as well as their combination reduced the percentage of the cells 
exhibiting ATP7BH1069Q in the ER and increases the number of cells in which the mutant 
was corrected to the Golgi. Single inhibitors and their mixture exhibit similar strength in 
correction of ATP7BH1069Q intracellular phenotype. ✻✻✻ - p<0.001; ✻✻ - p<0.01; ✻ - 
p<0.05; ns – p>0.05 (t-test). Scale bar: 5 μm (A). 
 
Sup. Fig. 4. Acute treatment with p38 or JNK inhibitor does not rescue ATP7BH1069Q 
mutant from the ER. 
(A) HeLa cells were infected with Ad-ATP7BH1069Q-GFP and incubated for 2h with 100 
μM CuSO4. p38 inhibitor or JNK inhibitor were added to the cells 1h before fixation (as 
indicated in corresponding panels). Fixed cells were than labeled for TGN46 and 
visualized under confocal microscope. Short-term treatment with either p38 orJNK 
inhibitor did not recover ATP7BH1069Q from the ER.  (B) Percentage of the cells (average 
± SD, n=10 fields) with ATP7B signal in the ER, was calculated. Both p38 and JNK 
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inhibitors did not reduce percentage of the cells that exhibit ATP7BH1069Q in the ER after 
1h treatment. Scale bar: 5 μm (A). 
 
Sup. Fig. 5. p38 and JNK inhibitors increase ATP7BH1069Q amounts in plasma 
membrane subcellular fraction. 
(A) HepG2 cells were infected with Ad-ATP7BWT-GFP and incubated for 2h with 100 
μM CuSO4. The cells were then subjected to subcellular fractionation (see Methods) and 
isolated membrane fractions labeled with different markers. Western blot indicates that 
ATP7BWT was enriched in fractions #5 and #10. However, fractions #2-5 were cross-
contaminated with ER (PDI), Golgi (GM130) and at some extent with plasma membrane 
(Na/K-ATPase) indicating poor separation between corresponding organelles. In contrast, 
fraction #10 contained only Na/K-ATPase demonstrating significant enrichment in 
plasma membranes (PMs). Therefore, Na/K-ATPase positive PM fractions were used 
further for evaluation of ATP7BWT or ATP7BH1069Q delivery to the cell surface. (B) 
HepG2 cells were infected with Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP and treated 
with CuSO4 and subjected to fractionation as in panel A. p38 inhibitor or JNK inhibitor 
were added to the cells 24h before fractionation procedure. Light PM fractions (#10-12) 
were prepared for Western blot and labeled with antibodies against GFP and against 
Na/K-ATPase. Na/K-ATPase-positive PM fractions from the p38 inhibitor- or JNK 
inhibitor-treated cells exhibit higher amounts of ATP7BH1069Q then the same fractions 
from untreated cells indicating that both inhibitors facilitate ATP7BH1069Q delivery to the 
cell surface. (C) ATP7B signal in fractions #10 (shown in panel B) was quantified using 
ImageJ software and normalized for Na/K-ATPase signal in corresponding lanes. Plot 
shows that both p38 and JNK inhibitors increase quantities of ATP7BH1069Q associated 
with PM fractions. 
 
Sup. Fig. 6. Suppression of p38 and JNK allows ATP7BH1069Q to reach canalicular 
surface of polarized HepG2 cells. 
HepG2 cells were grown at the conditions that allow their full polarization (see Methods). 
Then the cells were infected with Ad-ATP7BWT-GFP (A) or Ad-ATP7BH1069Q-GFP (B-
D) and incubated for 4h with 100 μM CuSO4. p38 (C) or JNK (D) inhibitors were added 
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to the cells 24h before fixation. Fixed cells were labeled for canalicular marker MRP2 
and visualized under confocal microscope. Cu induces delivery of ATP7BWT to the 
canalicular domain (A, arrows) while the mutant remains retained within the ER and does 
not reach the canalicular srface (B, arrows). Both p38 and JNK inhibitors allows 
ATP7BH1069Q to de delivered to the canalicular domain (C, D; arrows) in polarized 
HepG2 cells. Scale bar: 4 μm (A-D). 
 
Sup. Fig. 7. Inhibitors of p38 and JNK reduce copper levels in cells expressing 
ATP7BH1069Q mutant. 
HepG2 cells were infected with Ad-ATP7BWT-GFP (A) or Ad-ATP7BH1069Q-GFP (B-D), 
incubated for 2h with 100 μM CuSO4 and loaded with CS3 before fixation. p38 (C) or 
JNK (D) inhibitors was added to the cells 24h before fixation. (A, B) Cells expressing 
ATP7BH1069Q exhibit higher CS3 signal (and hence Cu levels) than cells expressing 
ATP7BWT. Arrows in B indicate ATP7BH1069Q –negative cells, which display CS3 levels 
similar to those detected in the neighbor cell expressing the mutant. This indicates that 
expression of mutant does not allow cells to efflux Cu efficiently. (C, D) Both p38 and 
JNK inhibitors decrease CS3 fluorescence in ATP7BH1069Q-expressing cells. Arrows in C 
and D show higher CS3 levels in cells expressing lower ATP7BH1069Q amounts, 
indicating that capacity of p38/JNK-inhibitor treated cells to eliminate Cu correlates to 
amount of the expressed mutant. Scale bar: 10 μm (A-D).  
 
Sup. Fig. 8. Inhibitors of p38 and JNK do not impact trafficking of VSVG. 
(A) HeLa cells were transfected with DNA encoding temperature-sensitive version of 
VSVG-GFP, incubated overnight at 40°C to block the newly-synthetized protein in the 
ER and fixed directly (left column) or incubated at 32°C for additional time periods (to 
activate VSVG-GFP trafficking) as indicated in panels. p38 inhibitor (mid row) or JNK 
inhibitor (bottom row) were added to the cells 24h before fixation. Fixed cells were than 
analyzed using confocal microscopy. Both p38 and JNK inhibitors did not affect VSVG 
delivery from the ER to the Golgi (arrowheads) and further to the PM (arrows). (B) 
Percentage of the cells (average ± SD, n=10 fields) with ATP7B signal in the ER, Golgi 
or PM was calculated. Cells exhibit similar dynamics of VSVG progression through the 
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5 
secretory pathway in control cells and in cells treated with p38 or JNK inhibitor. Scale 
bar: 5.2 μm (A). 
 
Sup. Fig. 9. p38 and JNK inhibitors does not affect interaction of ATP7BH1069Q with 
COMMD1. 
(A) HepG2 cells expressing COMMD1-GST were infected with Ad-ATP7BWT-GFP or 
Ad-ATP7BH1069Q-GFP, incubated for 2h with 100 μM CuSO4 and lysed. ATP7BWT and 
ATP7BH1069Q we pulled down from lysates using anti-GFP antibody. Both immuno-
precipitates (IPs) and total cell lysates were subjected to Western blot to reveal ATP7B 
and COMMD1. Western blot shows higher levels of COMMD1 in ATP7BH1069Q IP, 
indicating enhanced interaction of the mutant with COMMD1. (B) HepG2 cells 
expressing COMMD1-GST were infected with Ad-ATP7BH1069Q-GFP, treated with Cu 
and prepared for IP and Western blot as described in panel A. p38 or JNK inhibitor was 
added to the cells 24h before they were lysed. Neither inhibitor reduced COMMD1 
binding to ATP7BH1069Q, indicating that this interaction is unlikely to be involved in 
mutant correction by p38 or JNK inhibitors. 
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Gene 
Ontology (GO) 
Categories
Gene 
Ontology (GO)  
ID
Number of 
differentially 
expressed 
Genes with 
this GO 
category
Name of differentially expressed 
Genes with this GO category 
Population 
Hits (PH)
Population 
Total (PT)
Fold 
Enrichment 
(FE)
False 
Discovery 
Rate (FDR)
regulation of 
apoptosis
GO:0042981 41
CADM1, MCL1, CLU, TAF9B, SOX4, CDH1, 
CHEK2, SFN, PTEN, MAGED1, TDGF3, NOD2, 
TP53I3, CDKN2A, SQSTM1, CDKN2C, 
CDKN2D, AGT, TDGF1, PYCARD, FAIM, CAT, 
FAS, FOSL1, HELLS, MAP2K6, KNG1, TXNIP, 
DEPDC6, MSH6, LGALS1, ITGA1, SKP2, BIRC3, 
CDK5, SOD2, BNIP3L, AVEN, ID3, TNFAIP3, 
IGFBP3, IFI6
804 13528 2,41210034 5,78E-04
regulation of cell 
proliferation
GO:0042127 35
FGFR2, BLM, IFITM1, IL18, CLU, IFI30, SOX4, 
SFN, PTEN, TIMP1, TRIB1, MAGED1, CD47, 
WARS, TDGF3, CD9, CDKN2A, CDKN2C, 
CDKN2D, AGT, TDGF1, SERPINE1, FOSL1, 
TXNIP, STS, TESC, IL8, EGR4, SPARC, CDKN3, 
SOD2, CORO1A, CBLB, EREG, BTG3, IGFBP3
787 13528 2,10358891 0,092770639
response to drug GO:0042493 15
TXNIP, NAT8B, NAT8, MFSD9, MAT2A, CDH1, 
PTEN, SOD2, SERPINA7, CA9, ENO3, GNAS, 
LOX, FOSL1, PDZK1, MAP2K6
216 13528 3,28477078 0,341239702
regulation of cell 
cycle
GO:0051726 19
BLM, NEK2, SKP2, NUSAP1, ANAPC10, 
CHEK2, SFN, OBFC2A, CDKN3, CDK5, PTEN, 
CDT1, CDKN2A, EREG, CDKN2C, CDKN2D, 
BTG3, ID3, FOSL1
331 13528 2,71514588 0,404894167
regulation of 
cellular 
component size
GO:0032535 16
FGFR2, DEPDC6, TAF9B, SFN, CSRP2, 
N6AMT1, LEFTY1, CORO1A, CDKN2A, NDRG4, 
CDKN2C, MAPT, CDKN2D, AGT, TMSB4X, 
TMSL3
271 13528 2,79266121 1,099341419
oxidation 
reduction
GO:0055114 27
CYP24A1, SORD, PYROXD1, IFI30, GLDC, 
GPX2, TP53I3, P4HA2, P4HA1, PLOD2, IDH2, 
HSD17B6, BDH2, LOX, CAT, HADH, GPD1, 
NOX3, MTHFD2L, SOD2, OGFOD1, G6PD, 
BLVRB, PCYOX1, DIO1, GLYR1, AOC3
639 13528 1,9986211 1,758146094
positive regulation 
of immune system 
process
GO:0002684 14
MICB, BLM, CADM1, IL18, F2RL1, CLU, AQP3, 
CD47, CBLB, NOD2, CORO1A, EREG, SPG21, 
CFD
238 13528 2,78239408 2,783907866
DNA replication GO:0006260 12
POLD3, PRIM1, GINS2, RFC4, BLM, POLE2, 
DTL, MRE11A, CDKN2D, MCM10, CHAF1A, 
CDT1
190 13528 2,98741259 3,954136316
response to DNA 
damage stimulus
GO:0006974 18
EXO1, MSH6, NUDT1, BLM, DTL, MRE11A, 
SFN, CHEK2, OBFC2A, ATMIN, SOD2, POLD3, 
RFC4, POLE2, FANCI, CDKN2D, CHAF1A, 
MAP2K6
373 13528 2,28260747 4,081799187
regulation of cell 
adhesion
GO:0030155 10
KNG1, CD47, TDGF3, TESC, CDKN2A, IL8, 
IL18, TDGF1, SERPINI1, PTEN, DPP4
137 13528 3,45260579 4,180275525
SUPPLEMENTARY TABLE 1. 
Gene ontology (GO) categories of genes differentially expressed in ATP7B-H1069Q 
expressing cells versus ATP7B-WT expressing cells. 
Gene ontology descriptions of biological processes were assigned on the basis of the informations retrieved from DAVID 
(http://david.abcc.ncifcrf.gov/), considering a False Discovery Rate (FDR) less than 5; Population Hits (PH) corresponds to the number of 
genes of each GO category on the whole background list; Population Total (PT) corresponds to the total number of genes on the whole 
background list; Fold Enrichment (FE) estimates the enrichment degree of the corresponding GO category
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Protein CODE SP GENE NAME # Peptides MW [kDa]
Transferrin receptor protein 1 P02786 TFRC 4 85
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
LAVDEEENADNNTK 53 2 1561.73 22.5
LLNENSYVPR 18 2 1204.81 250
SSGLPNIPVQTISR 28 2 1468.97 96
VEYHFLSPYVSPK 15 3 1566.08 183
Guanine nucleotide-binding protein subunit beta-2-like 1 P63244 GNB2L1 11 35
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
IIVDELKQEVISTSSK 79 2 1789.27 155
VWQVTIGTR 47 2 1059.69 92.7
LWDLTTGTTTR 46 2 1264.85 158
YWLCAATGPSIK 46 2 1366.93 183
LWDLTTGTTTRR 36 3 1421.03 198
DETNYGIPQR 36 2 1192.63 61.6
LTRDETNYGIPQR 33 3 1562.96 111
VWNLANCK 32 2 1004.63 134
FSPNSSNPIIVSCGWDK 45 2 1907.94 29.9
IWDLEGK 26 2 860.61 188
60S ribosomal protein L7 P18124 RPL7 8 29
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
IVEPYIAWGYPNLK 81 2 1663.17 123
IALTDNALIAR 71 2 1170.81 195
SVNELIYKR 38 2 1121.69 54.8
ASINMLR 35 2 804.51 91
EVPAVPETLK 34 2 1082.65 40.3
QIFNGTFVK 33 2 1053.77 190
SVNELIYK 32 2 965.63 106
AGNFYVPAEPK 30 2 1192.75 128
ADP/ATP translocase 3 P12236 SLC25A6 7 33
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
DFLAGGIAAAISK 99 2 1233.89 170
YFPTQALNFAFK 54 2 1446.97 160
LLLQVQHASK 39 2 1136.79 100
GNLANVIR 38 2 856.53 38.4
GAWSNVLR 35 2 902.61 75.9
AAYFGVYDTAK 32 2 1205.73 124
EQGVLSFWR 26 2 1121.81 178
Vesicle-associated membrane protein-associated protein B/C O95292 VAPB 3 27
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GPFTDVVTTNLK 66 2 1291.81 95.7
TVQSNSPISALAPTGK 51 2 1570.79 5.87
FRGPFTDVVTTNLK 15 3 1595.24 243
Glutathione S-transferase omega-1 P78417 GSTO1 6 27
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VPSLVGSFIR 51 2 1074.73 151
HEVININLK 46 2 1079.71 85.3
GSAPPGPVPEGSIR 32 2 1320.79 77.4
LLPDDPYEK 31 2 1089.65 135
FCPFAER 17 2 925.56 166
EFTKLEEVLTNK 17 3 1450.88 73.6
Ribonucleoside-diphosphate reductase subunit M2 P31350 RRM2 2 51
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
FSQEVQITEAR 67 2 1307.61 -35.41
IEQEFLTEALPVK 58 2 1516.95 83.8
14-3-3 protein eta Q04917 YWHAH 2 28
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
AVTELNEPLSNEDR 82 2 1586.85 54.9
NSVVEASEAAYK 58 2 1267.65 28.6
LIM domain only protein 7 Q8WWI1 LMO7 4 158
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TSTTGVATTQSPTPR 74 2 1504.79 21.6
ISINQTPGK 45 2 957.61 79.8
WIDATSGIYNSEK 38 2 1484.33 422
RGESLDNLDSPR 35 3 1358.96 221
ATP-dependent Clp protease ATP-binding subunit clpX-like, mit O76031 CLPX 5 58
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
DVGGEGVQQGLLK 68 2 1299.67 -13.55
LLEGTIVNVPEK 47 2 1312.03 214
LLQDANYNVEK 32 2 1306.89 175
SUPPLEMENTARY TABLE 2. List of ATP7B-WT-specific interactors.
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SIIKEPESAAEAVK 28 3 1472.33 364
TLLAQTLAK 28 2 958.75 167
Eukaryotic translation initiation factor 4 gamma 2 P78344 EIF4G2 2 102
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TQTPPLGQTPQLGLK 68 2 1578.97 55.6
SYLAQFAAR 59 2 1026.67 133
Estradiol 17-beta-dehydrogenase 8 Q92506  HSD17B8 2 27
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SALALVTGAGSGIGR 91 2 1329.87 93.3
AGVIGLTQTAAR 55 2 1157.69 25
signal recognition particle receptor subunit beta Q9Y5M8 SRPRB 5 30
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SAAPSTLDSSSTAPAQLGK 77 2 1788.97 42.1
GDVGSADIQDLEK 63 2 1346.81 126
VADGGGAGGTFQPYLDTLR 53 2 1894.98 33.4
SAAPSTLDSSSTAPAQLGKK 24 3 1916.99 1.62
LQFLER 22 2 805.55 119
Cell cycle and apoptosis regulator protein 2 Q8N163 DBC1 6 103
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TLAAEMQELR 56 2 1161.67 68.5
VQTLSNQPLLK 45 2 1240.87 118
FSATEVTNK 34 2 996.65 154
LTPLQLEIQR 28 2 1210.89 147
SPAPPLLHVAALGQK 27 3 1499.03 108
IQVSSEKEAAPDAGAEPITADSDPAYSSK 25 3 2934.28 -30.54
ATP synthase subunit gamma, mitochondrial P36542 ATP5C1 3 33
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
IYGLGSLALYEK 51 2 1326.91 138
SEVATLTAAGK 44 2 1047.73 157
HLLIGVSSDR 41 2 1096.61 1.64
Large proline-rich protein BAG6 P46379 BAG6 3 114
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
AGSSESIAAFIQR 64 2 1336.85 110
LINLVGESLR 36 2 1113.89 207
LQEDPNYSPQRFPNAQR 24 3 2060.17 92.8
Ubiquitin-associated protein 2 Q5T6F2 UBAP2 3 117
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
DGSLANNPYPGDVTK 63 2 1547.79 38.2
SQPEPSPVLSQLSQR 32 2 1652.93 43.9
AAPLVTSGK 28 2 843.53 46.6
Ran-specific GTPase-activating protein P43487 RANBP1 2 23
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TLEEDEEELFK 55 2 1381.89 185
FASENDLPEWKER 44 3 1621.01 154
Cation-independent mannose-6-phosphate receptor P11717  IGF2R 2 266
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VPIDGPPIDIGR 48 2 1248.91 175
YDLSALVR 37 2 936.75 254
B-cell receptor-associated protein 31 P51572 BCAP31 2 28
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
LDVGNAEVKLEEENR 59 3 1715.09 137
AENQVLAMR 51 2 1031.67 138
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 O43678 NDUFA2 2 11
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
ALENVLSGKA 45 2 1001.64 90.1
YAFGQETNVPLNNFSADQVTR 55 3 2371.25 52.4
Inositol-3-phosphate synthase 1 Q9NPH2 ISYNA1 3 61
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VGPVAATYPMLNK 50 2 1360.93 150
ADNLIPGSR 27 2 942.71 226
VFVGGDDFK 21 2 983.69 213
EH domain-containing protein 1 Q9H4M9 EHD1 3 61
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
LLDTVDDmLANDIAR M8(Oxidation) 61 2 1691.01 107
HLIEQDFPGMR 18 2 1343.29 474
KLNAFGNAFLNR 10 3 1364.51 -167.09
5'-3' exoribonuclease 2 Q9H0D6 XRN2 3 109
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
NSLGGDVLFVGK 53 2 1205.88 199
GVGAEPLLPWNR 18 2 1308.9 158
AALEEVYPDLTPEETRR 50 3 1989.17 92.1
60S acidic ribosomal protein P1 P05386  RPLP1 2 12
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
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KEESEESDDDMGFGLFD 62 2 1949.9 78.7
AAGVNVEPFWPGLFAK 55 2 1703.03 80.8
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 O95168 NDUFB4 3 15
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TLPETLDPAEYNISPETR 56 2 2045.96 -14.59
GLIENPALLR 53 2 1095.73 73.7
TINVYPNFRPTPK 20 2 1547.57 476
Conserved oligomeric Golgi complex subunit 5 Q9UP83 COG5, 2 91
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
NPPSSDELDGIIK 47 2 1384.67 -16.41
STMPTPGNTAALR 19 2 1316.95 220
Protein transport protein Sec24C P53992 SEC24C 3 118
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SPVESTTEPPAVR 45 2 1369.77 56.2
GTEPFVTGVR 22 2 1062.69 127
YASFQVENDQER 11 2 1485.77 75.6
14-3-3 protein theta P27348 YWHAQ 2 28
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
qTIDNSQGAYQEAFDISK N-Term(Gln->pyro-Glu) 71 2 1997.9 2.02
QTIDNSQGAYQEAFDISKK 46 3 2143.09 35.1
Licensed MASCOT software (Matrix Science, UK) was used to unambiguously identify proteins from NCBInr sequence database. NanoLC-
MS/MS data were searched using a mass tolerance value of 600 ppm for precursor ion and 0.6 Da for MS/MS fragments, trypsin as the 
proteolytic enzyme, a missed cleavages maximum value of 1, and Cys carbamidomethylation as fixed modification, and pyroglutamate (peptide N-
terminal Gln), pyro-carbamidomethyl Cys (peptide N-terminal CAM-Cys) and Met oxidation as variable modifications. Possible charge states +2 
and +3. Candidates with almost 2 assigned peptides with an individual MASCOT score > 44 (p<0.05) were considered significant. Protein gene 
names and UniProt codes were reported as well as the sequence and charge state of each peptide used for identification, the MH+ values, and 
the error expressed in ppm.
Page 49 of 60
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
PROTEIN UNIPROT CODE GENE NAME # Peptides MW [kDa]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 P19174 PLCG1 3 161
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SGDITYGQFAQLYR 81 2 1618.87 53.60
TmDLPFLEASTLR M2(Oxidation) 56 2 1510.01 166.00
APLFPAPK 27 2 840.75 280.00
Golgi apparatus protein 1 Q92896 GLG1 2 134
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VAELSSDDFHLDR 59 3 1504.01 205.00
IIIQESALDYR 58 2 1320.91 149.00
Integrin beta-1 P05556 ITGB1 4 88
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SAVTTVVNPK 67 2 1015.15 -419.41
IGFGSFVEK 37 2 983.67 156.00
LKPEDITQIQPQQLVLR 31 3 2019.52 186.00
SGEPQTFTLK 19 2 1107.65 76.50
T-complex protein 1 subunit beta P78371 CCT2 8 57
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
EALLSSAVDHGSDEVK 70 2 1656.77 -21.01
GATQQILDEAER 61 2 1330.67 9.79
HGINCFINR 48 2 1130.67 107.00
QDLmNIAGTTLSSK M4(Oxidation) 38 2 1494.89 97.70
VLVDMSR 32 2 819.57 163.00
AAHSEGNTTAGLDMR 15 3 1530.77 51.60
ILIANTGMDTDKIK 44 3 1532.92 65.40
NIGVDNPAAK 21 2 998.63 66.40
60S ribosomal protein L18 Q07020 RPL18 5 18
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
ILTFDQLALDSPK 58 2 1461.01 187.00
TAVVVGTITDDVR 75 2 1345.89 -14.49
GCGTVLLSGPR 52 2 1116.75 152.00
TNSTFNQVVLK 44 2 1250.73 47.00
SQDIYLR 17 2 894.53 72.50
Proteasome activator complex subunit 1 Q06323 PSME1 8 28
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TENLLGSYFPK 61 2 1268.91 206.00
IEDGNNFGVAVQEK 77 2 1519.81 101.00
qLVHELDEAEYR N-Term(Gln->pyro-Glu) 48 2 1484.83 88.40
APLDIPVPDPVKEK 40 3 1518.47 407.00
LmVMEIR M2(Oxidation) 39 2 907.67 219.00
IVVLLQR 22 2 840.75 222.00
qPHVGDYR N-Term(Gln->pyro-Glu) 19 2 954.61 178.00
qLVHELDEAEYRDIR N-Term(Gln->pyro-Glu) 28 3 1869.28 204.00
CALNEXIN P27824 CANX 7 71
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
IVDDWANDGWGLK 77 2 1488.87 108.00
APVPTGEVYFADSFDR 67 2 1770.83 -0.36
GTLSGWILSK 53 2 1061.73 126.00
IVDDWANDGWGLKK 46 3 1617.02 135.00
TPYTImFGPDK M6(Oxidation) 46 2 1285.77 124.00
LPGDKGLVLmSR M10(Oxidation) 28 3 1301.87 116.00
IPDPEAVKPDDWDEDAPAK 43 3 2108.02 25.40
Aldehyde dehydrogenase X, mitochondrial P30837 ALDH1B1 4 57
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
LAPALATGNTVVMK 63 2 1385.95 123.00
IAKEEIFGPVQPLFK 43 3 1716.35 223.00
VAEQTPLSALYLASLIK 86 2 1817.30 149.00
VTLELGGK 31 2 816.51 37.00
T-complex protein 1 subunit epsilon P48643 CCT5 6 59.43073302
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
qQISLATQmVR
N-Term(Gln->pyro-Glu);           
M9(Oxidation)
78 2 1273.75 75.30
IAILTcPFEPPKPK C6(Carbamidomethyl) 55 3 1611.47 359.00
GVIVDKDFSHPQmPK M13(Oxidation) 47 3 1714.85 579.00
TSLGPDGLDK 16 2 1002.54 42.40
LMGLEALK 31 2 874.67 190.00
MLVIEQcK C7(Carbamidomethyl) 28 2 1020.51 -8.74
40S ribosomal protein S21 P63220 RPS21 4 8
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
MGESDDSILR 66 2 1122.57 38.50
TYAIcGAIR C5(Carbamidomethyl) 34 2 1024.53 8.12
RMGESDDSILR 28 2 1278.77 127.00
SUPPLEMENTARY TABLE 3. List of ATP7B-H1069Q-specific interactors.
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DHASIQmNVAEVDKVTGR M7(Oxidation) 50 3 1987 526.00
6-phosphogluconate dehydrogenase, decarboxylating P52209 PGD 6 50
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GILFVGSGVSGGEEGAR 88 2 1591.87 41.00
VDDFLANEAK 53 2 1121.67 112.00
TVSKVDDFLANEAK 44 2 1536.87 53.60
AGQAVDDFIEK 41 2 1192.61 23.70
TIFQGIAAK 28 2 948.67 128.00
SFLEDIRK 17 2 1007.07 -476.16
DNA replication licensing factor MCM3 P25205 MCM3 6 91
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TPmENIGLQDSLLSR M3(Oxidation) 93 2 1689.69 -91.70
GDINILLIGDPSVAK 62 2 1524.31 -361.22
GSSGVGLTAAVTTDQETGER 91 2 1935.92 3.77
VALLDVFR 33 2 932.73 189.00
TLETLIR 33 2 845.69 217.00
LIVNVNDLRR 21 3 1211.9 152.00
40S ribosomal protein S27 P42677 RPS27 2 10
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
LVQSPNSYFmDVK M10(Oxidation) 72 2 1543.79 30.20
LTEGcSFR C5(Carbamidomethyl) 31 2 969.51 69.10
Interleukin enhancer-binding factor 3 Q12906 ILF3 7 75
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
AYAALAALEK 57 2 1020.69 118.00
EDITQSAQHALR 52 2 1368.57 -83.26
VLQDMGLPTGAEGR 50 2 1443.85 87.80
LFPDTPLALDANK 38 2 1414.77 10.70
VLGMDPLPSK 37 2 1056.75 168.00
LNQLKPGLQYK 27 3 1301.63 160.00
LAAFGQLHK 21 2 984.65 91.70
Peptidyl-prolyl cis-trans isomerase FKBP1A P62942 FKBP1A 3 12
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GVQVETISPGDGR 62 2 1314.75 66.90
GWEEGVAQMSVGQR 57 2 1533.73 13.90
GVQVETISPGDGRTFPK 45 3 1788.11 105.00
Heat shock 70 kDa protein 4L O95757 HSPA4L 2 97
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
DISTTLNADEAVAR 85 2 1475.73 -0.60
VLATTFDPYLGGR 64 2 1409.95 149.00
Programmed cell death protein 5 O14737  PDCD5 3 13
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
NSILAQVLDQSAR 84 2 1414.93 119.00
AVENYLIQmAR M9(Oxidation) 64 2 1323.43 -181.29
LSNLALVKPEK 18 3 1211.93 165.00
tRNA-splicing ligase RtcB homolog Q9Y3I0 HSPC117 4 55
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
qIGNVAALPGIVHR N-Term(Gln->pyro-Glu) 59 2 1428.01 141.00
SYNDELQFLEK 56 2 1385.79 97.10
IASPEGQDYLK 42 2 1220.79 145.00
SSmTFLTR M3(Oxidation) 29 2 958.53 69.40
Proteasome activator complex subunit 2 Q9UL46 PSME2 5 27
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
IEDGNDFGVAIQEK 68 2 1534.89 101.00
ALVHERDEAAYGELR 55 3 1729.01 86.30
TKVEAFQTTISK 33 2 1352.85 81.90
cGFLPGNEK C1(Carbamidomethyl) 29 2 1021.57 93.70
AmVLDLR M2(Oxidation) 28 2 833.59 166.00
cytochrome c oxidase subunit 5B, mitochondrial precursor Q6FHJ9 COX5B 3 14
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GLDPYNVLAPK 56 2 1186.69 38.90
KGLDPYNVLAPK 47 3 1315.06 254.00
LVPQQLAH 19 2 905.53 13.70
Cytochrome c oxidase subunit 5A, mitochondrial P20674 COX5A 4 17
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GINTLVTYDmVPEPK M10(Oxidation) 55 2 1692.91 36.30
LNDFASTVR 47 2 1022.59 64.80
ILEVVKDK 34 2 943.67 96.00
RLNDFASTVR 28 2 1178.85 191.00
Elongation factor 1-beta P24534 EEF1B2 2 25
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SPAGLQVLNDYLADK 88 2 1604.13 187.00
SIQADGLVWGSSK 57 2 1347.77 61.20
ATP synthase subunit e, mitochondrial P56385 ATP5I 3 8
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
YSALFLGVAYGATR 45 2 1488.21 -384.33
VPPVQVSPLIK 45 2 1176.81 66.00
ELAEDDSILK 44 2 1132.69 106.00
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Thioredoxin domain-containing protein 5 Q8NBS9 TXNDC5 5 44
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GYPTLLWFR 46 2 1152.83 185.00
GYPTLLLFR 45 2 1079.79 156.00
FVLSQAKDEL 39 2 1149.85 207.00
EFPGLAGVK 29 2 917.65 157.00
TLAPTWEELSK 18 2 1274.75 70.70
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial P10515 DLAT 3 69
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GVETIANDVVSLATK 99 2 1516.97 99.60
GIDLTQVK 39 2 873.47 -35.86
ILVPEGTR 17 2 884.59 82.30
28S ribosomal protein S28, mitochondrial Q9Y2Q9 MRPS28 2 20
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
NVESFASmLR M8(Oxidation) 53 2 1169.75 163.00
LLDLELTSR 52 2 1059.832723 216.00
Ubiquitin thioesterase OTUB1 Q96FW1 OTUB1 2 46
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
IQQEIAVQNPLVSER 68 2 1723.93 -0.57
LLTSGYLQR 41 2 1050.33 -249.13
EH domain-containing protein 4 Q9H223 EHD4 3 61
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
AGGADAVQTVTGGLR 63 2 1372.77 39.90
SISVIDSPGILSGEK 44 2 1502.25 294.00
EYQISAGDFPEVK 30 2 1482.89 123.00
Acetyl-CoA acetyltransferase, cytosolic Q9BWD1 ACAT2 6 41
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GLIEVKTDEFPR 78 3 1404.02 173.00
VAVLSQNR 40 2 886.79 319.00
ILVTLLHTLER 31 3 1308.14 261.00
VNIEGGAIALGHPLGASGCR 58 3 1949.17 94.1
ELGLNPEK 18 2 899.55 77.30
APHLAYLR 18 2 940.43 -110.22
Fibrinogen gamma chain P02679 FGG 5 49
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
YLQEIYNSNNQK 60 2 1513.95 148.00
TSTADYAmFK M8(Oxidation) 38 2 1150.57 55.90
qSGLYFIKPLK N-Term(Gln->pyro-Glu) 30 2 1276.89 128.00
VELEDWNGR 21 2 1117.73 184.00
AIQLTYNPDESSKPNmIDAATLK M16(Oxidation) 61 3 2536.21 -13.59
Alpha-aminoadipic semialdehyde dehydrogenase P49419 ALDH7A1 4 54
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VNLLSFTGSTQVGK 59 2 1451.15 250.00
QGLSSSIFTK 46 2 1067.67 93.40
MIGGPILPSER 33 2 1169.79 135.00
VGNPWDPNVLYGPLHTK 40 3 1907.41 233.00
26S proteasome non-ATPase regulatory subunit 2 Q13200 PSMD2 3 94
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VGQAVDVVGQAGKPK 57 3 1453.06 178.00
ELDIMEPKVPDDIYK 34 3 1805.2 173.00
mLVTFDEELRPLPVSVR M1(Oxidation) 58 3 2018.26 2.37
26S proteasome non-ATPase regulatory subunit 7 P51665  PSMD7 2 28
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
DIKDTTVGTLSQR 63 2 1433.75 -4.70
SVVALHNLINNK 57 2 1321.87 86.40
E3 UFM1-protein ligase 1 [Homo sapiens] O94874 UFL1 5 89
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
FFADDTQAALTK 49 2 1327.17 -361.92
AVFVPDIYSR 32 2 1166.77 131.00
SVFMSSTTSASGTGR 31 2 1475.73 36.10
LAADFQR 22 2 820.47 50.70
TYLEVVR 17 2 879.69 227.00
Protein transport protein Sec61 subunit beta P60468 SEC61B 2 10
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TTSAGTGGMWR 49 2 1124.49 -20.12
FYTEDSPGLK 33 2 1156.65 17.90
26S proteasome non-ATPase regulatory subunit 13 Q9UNM6 PSMD13 5 35
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VLDLQQIK 48 2 956.67 99.70
LNIGDLQVTK 44 2 1100.69 56.10
QLTFEEIAK 40 2 1078.79 199.00
QmTDPNVALTFLEK M2(Oxidation) 22 2 1623.05 150.00
FLGCVDIKDLPVSEQQER 37 3 2133.37 151.00
Small nuclear ribonucleoprotein E P62304 SNRPE 3 11
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
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VmVQPINLIFR M2(Oxidation) 53 2 1345.89 94.20
ImLKGDNITLLQSVSN M2(Oxidation) 38 2 1761.95 6.38
GDNITLLQSVSN 33 2 1260.79 119.00
Nuclear migration protein nudC Q9Y266 NUDC 2 38
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GQPAIIDGELYNEVK 54 2 1645.81 -18.50
LVSSDPEINTK 45 2 1202.75 105.00
Ubiquitin carboxyl-terminal hydrolase isozyme L3 P15374 UCHL3 2 22
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
FLEESVSMSPEER 52 2 1539.69 -4.42
YLENYDAIR 47 2 1156.79 199.00
Ubiquitin conjugation factor E4 A Q14139 UBE4A 2 120
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SYSPTLFAQTVR 58 2 1369.85 104.00
VFVEYIQPK 37 2 1122.87 226.00
Lymphokine-activated killer T-cell-originated protein kinase Q96KB5 PBK 2 36
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
ASQDPFPAAIILK 57 2 1370.91 106.00
SLNDLIEER 44 2 1088.65 86.90
Cystatin-B P04080 CSTB 2 11
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
SQVVAGTNYFIK 60 2 1326.83 96.20
AKHDELTYF 21 2 1123.65 98.80
Mitogen-activated protein kinase 14 Q16539  MAPK14 2 41
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
NYIQSLTQmPK M9(Oxidation) 48 2 1338.53 -104.26
ILDFGLAR 38 2 904.67 163.00
Asparagine--tRNA ligase, cytoplasmic O43776 NARS 3 63
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
IFDSEEILAGYKR 45 3 1540.97 114.00
SPAGSIVHELNPNFQPPK 36 3 1931.15 -436.01
IGALEGYR 31 2 878.67 228.00
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 
DAD1 P61803 DAD1 2 12
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
FLEEYLSSTPQR 48 2 1469.79 44.70
SASVVSVISR 28 2 1005.03 458.00
Nucleophosmin P06748 NPM1 2 25
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
GPSSVEDIK 47 2 931.55 85.60
LLSISGKR 11 2 873.47 -90.40
6-phosphofructokinase, liver type P17858 PFKL 3 90
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
VFANAPDSAcVIGLK C10(Carbamidomethyl) 45 2 1561.95 95.10
AIGVLTSGGDAQGmNAAVR M14(Oxidation) 82 2 1803.92 17.20
IMEVIDAITTTAQSHQR 47 3 1914.35 199.00
Acyl-CoA-binding protein P07108 DBI 2 10
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
TKPSDEEmLFIYGHYK M8(Oxidation) 41 3 1973.96 17.30
QATVGDINTERPGMLDFTGK 48 3 2150.24 88.80
S-methyl-5'-thioadenosine phosphorylase Q13126 MTAP 2 32
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
YVDTPFGKPSDALILGK 47 3 1821.29 174.00
IGIIGGTGLDDPEILEGRTEK 46 3 2183.39 110.00
Hsp90 co-chaperone Cdc37 Q16543 CDC37 3 44
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
ASEAKEGEEAGPGDPLLEAVPK 51 3 2195.3 555.00
EGEEAGPGDPLLEAVPK 28 2 1708.04 123.00
LQAEAQQLR 16 2 1056.74 164.00
Alanine aminotransferase 2 Q8TD30 GPT2 3 58
Peptide Sequences Modifications IonScore Charge MH+ [Da] ΔM [ppm]
KPFTEVIR 13 2 989.66 96.00
MTILPPVEK 27 2 1027.68 104.00
ANIGDAQAMGQQPITFLR 68 2 1931.04 37.50
Licensed MASCOT software (Matrix Science, UK) was used to unambiguously identify proteins from NCBInr sequence database. NanoLC-MS/MS data 
were searched using a mass tolerance value of 600 ppm for precursor ion and 0.6 Da for MS/MS fragments, trypsin as the proteolytic enzyme, a missed 
cleavages maximum value of 1, and Cys carbamidomethylation as fixed modification, and pyroglutamate (peptide N-terminal Gln), pyro-
carbamidomethyl Cys (peptide N-terminal CAM-Cys) and Met oxidation as variable modifications. Possible charge states +2 and +3. Candidates with 
almost 2 assigned peptides with an individual MASCOT score > 44 (p<0.05) were considered significant. Protein gene names and UniProt codes were 
reported as well as the sequence and charge state of each peptide used for identification, the MH+ values, and the error expressed in ppm.
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SUPPLEMENTARY MATERIALS AND METHODS 
 
Antibodies, Reagents, DNAs and Adenoviruses 
 
The following antibodies were used. Anti-α-tubulin was from Sigma-Aldrich (St. Louis, 
USA), anti-TGN46 from AbD Serotec (Oxford, UK), anti-MRP2 from Enzo Life 
Sciences (Lausen, Switzerland), anti-GM130, anti-giantin and anti-GFP from Abcam 
(Cambridge, UK), phospho-p38, phospho-JNK, phosphor-ERK, p38, JNK and ERK (Cell 
Signaling Techology, Beverly MA USA) anti- secondary Alexa Fluor 488, 568, 633, 647-
conjugated antibodies were from Invitrogen-Life Technologies (Grand Island, USA), 
secondary peroxidase conjugate antibodies were from Calbiochem (Darmstadt, 
Germany). GoldEnhance™ EM kit and 1.4nm gold-conjugated Fab' fragment of anti-
rabbit IgGs were from Nanoprobes (Yaphank, NY 11980-9710, USA). The DNAs of 
GFP-tagged ATP7B and ATP7BH1069Q were provided by Svetlana Lutsenko (John 
Hopkins Medical School, Baltimore, MD, USA) and by Dominik Huster (University of 
Leipzig, Leipzig, Germany). The cDNAs of transcription-based luciferase reporter 
(pGL3-E1b-TATA-4MRE) as well as DNAs of ATP7A and its mutants were reported 
before (13).  DNAs of flag-tagged MKK3, 4, 6 and 7 were obtained from Addgene 
(Cambridge MA, USA). To obtain the R778L, D765N, L776V, A874V and L1083F 
mutants of ATP7B, the pEGFPC1-ATP7B construct was used as a template, and site-
direct mutagenesis was performed according to the manufacturer instructions for site-
directed mutagenesis using the QuickChange kit (Stratagene, La Jolla, CA, USA). 
Recombinant adenoviruses containing ATP7B-GFP or ATP7BH1069Q-GFP were reported 
before (14). 
 
Cell culture and Treatments 
HeLa, HepG2 cells and primary mouse hepatocytes were grown in Dulbecco’s Modified 
Eagle’s medium (DMEM) supplemented with FCS 10% (decomplemented for HepG2 
cells), L-glutamine and Penicillin/Streptomycin. HeLa, HepG2 cells and primary 
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hepatocytes were treated with 200 μM Cu-chelating agent BCS overnight or with 100-
200 μM CuSO4 in culture medium at 37°C for 2 or 8 h. To inhibit p38 or JNK specific 
inhibitors SB202190 (Sigma Aldrich, USA) or SP600125 (Sigma Aldrich, USA) were 
used respectively. To inhibit protein biosynthesis Cycloheximide (Sigma Aldrich, USA) 
100 μg/mL was used at 2,4 and 6 hours. To inhibit the proteasome MG132 (Sigma) 
20μM for 4 hours was used. 
 
Adenoviral Infection, DNA Transfection, RNA interference, RNA Preparation and 
Q-PCR  
HeLa and HepG2 cells were infected with first generation adenovirus containing ATP7B-
GFP or ATP7BH1069Q-GFP respectively with a multiplicity of infection (MOI) of 50 and 
200 virus particles per cell respectively. HepG2 or HeLa cells were transiently 
transfected with jetPEI TM-Hepatocyte or Trans IT LT1 Transfection transfection 
reagents (Polyplus transfection, New York NY USA) respectively. siRNAs targeting 
MAPK8, MAPK9, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAP3K11 
were purchased from Sigma-Aldrich and transfected using Oligofectamine (Invitrogen, 
Carlsbad USA). Total RNAs from control cells and silenced HeLa cells were purified 
with the using QIA shredder and extracted with RNeasy Protect Mini Kit. Total RNA 
was converted into cDNA with QuantiTect Reverse Transcription kit. Q-PCR 
experiments were performed using Light Cycler 480 Syber Green MasterMix for cDNA 
amplification and in LightCycler 480 II for signal detection. Q-PCR results were 
analyzed using the comparative Ct method normalized against housekeeping gene β-
Actin. 
 
VSVG trafficking assay. 
To evaluate the impact of p38 and JNK inhibitors on overall membrane trafficking 
thermo-sensitive form of vesicular stomatitis virus glycoprotein fused with GFP (VSVG-
GFP) was transfected into HeLa cells. Control and inhibitor-treated cells were incubated 
at 40°C to accumulate VSVG in the ER. Then the temperature was shifted to 32°C to 
activate VSVG-GFP trafficking. Cells were fixed at different time intervals after the 
temperature shift and analyzed using confocal microscopy. 
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Immunofluorescence 
Cells were fixed for 10 min with 4% paraformaldehyde (PFA) in 0.2 M HEPES followed 
by incubation with blocking/permeabilizing solution: 0.5% bovine serum albumin (BSA), 
0.1% saponin, 50 mM NH4Cl in PBS for 20-30 min. Primary and secondary antibodies 
were diluted in blocking/permeabilizing solution and added to the cells for 1h/overnight 
or 45 min respectively. Samples were examined with a ZEISS LSM 700 or LSM 710 
confocal microscopes equipped with a 63X 1.4 NA oil objective.  
For fluorescent Cu detection with CS3 cells were incubated with 5 μM CS3 
(kindly provided by Christopher Chang, Berkeley USA) for 15 min at 37°C. CS3 was 
excited with 561 nm laser of LSM710 and its emission was collected from 565 to 650 
nm. Co-localization module of ZEISS ZEN 2008 software was used to measure co-
localization of ATP7B with different intracellular markers. ATP7B fluorescent signal 
inside canalicular domains and CS3 cytosolic and canalicular surface signals were 
measured using ZEISS ZEN 2008 software and reported in arbitrary units (au).  
 
Fluorescent recovery after photobleaching (FRAP) 
Time-lapse sequences from control and inhibitor-treated HeLa cells expressing 
ATP7BH1069Q-GFP were taken at ZEISS LSM 700 or LSM 710 confocal stages at 37°C. 
Digital images were collected at 3-second intervals. Selective photobleaching of GFP in 
the Golgi regions was carried out using 100 consecutive scans with a 488 nm laser line at 
full power. Average fluorescence intensities and t1/2 of the recovery in the Golgi regions 
were quantified using FRAP module of ZEISS ZEN 2008 software.  
 
Western blot analysis 
Cells were then solubilized in RIPA buffer. The protein concentration in each sample was 
evaluated using Bradford Protein Assay. Proteins were eluted with SDS sample buffer 
and analyzed by immunoblot analysis. Antibodies against GFP, tubulin, phospho-p38, 
phospho-JNK, p38 and JNK were used. 
 
Immunoprecipitation and mass spectrometry analysis 
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To identify the effects of ATP7B H1069Q overexpression on the proteome of liver cell line, 
proteomics analysis was performed. For the analysis of the hepatocytes overexpressing 
ATP7BH1069Q-GFP or ATP7BWT-GFP, cell lysates were incubated with the anti-GFP 
antibody. Then protein G sepharose beads (Sigma, St Louis, MO, USA) were added to 
each specimen and immune complexes were collected by centrifugation. The beads were 
then washed and immunoprecipitated proteins were eluted. The eluted proteins were 
precipitated in methanol/chloroform and then separated by SDS-PAGE. The gel was 
stained with Coomassie blue. Protein bands were excised from the gel, and digested with 
trypsin. Peptide mixtures extracted from the gel were analyzed by nano-chromatography 
tandem mass spectrometry (nanoLC–MS/MS) on a CHIP MS Ion Trap XCT Ultra 
equipped with a capillary 1100 HPLC system and a chip cube (Agilent Technologies, 
Palo Alto, CA). Peptide analysis was performed using data-dependent acquisition of one 
MS scan (mass range from 400 to 2000 m/z) followed by MS/MS scans of the three most 
abundant ions in each MS scan. Raw data from nanoLC–MS/MS analyses were 
employed to query a nonredundant protein database using in house MASCOT software 
(Matrix Science, Boston, USA).  
 
Subcellular fractionation 
To determine the amount of ATP7B protein in in different cellular compartments HepG2 
expressing ATP7BWT-GFP or ATP7BH1069Q-GFP (control and treated with p38 or JNK 
inhibitors) were subjected to subcellular fractionation as described in Balch et al (1984). 
Cells homogenates were separated using discontinuous sucrose density gradient 
centrifugation. Fractions were collected at in 1.5 ml tubes by aspiration from the bottom, 
through a capillary tube attached to a polyethylene tube connected to a peristaltic pump 
and a fraction collector (total of 14 fractions – ~850 μl each). GM130 was used as marker 
of the Golgi, PDI  of the  ER and Sodium/Potassium ATPase of plasma membrane. 
Amonts of GM130, PDI, Na/K-ATPase and ATP7B were revealed in each fractions by 
Western blot. Briefly, 90 μl of each fraction was mixed with reducing buffer and boiled 
for 5 min. Samples were loaded in 10% BIS-TRIS gels and run under denaturing 
conditions. Gels were transferred to nitrocellulose membranes blocked with 1% BSA and 
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icubated with antibodies against GM130, GFP, PDI or Na/K-ATPase. Anti-rabbit and 
anti-mouse HRP-conjugated antibodies were used to reveal primary antibodies.  
 
Copper detection by Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) 
To determine intracellular Cu concentrations, cell pellets were lysed. The protein 
concentration in each sample was evaluated using Bradford Protein Assay (BioRad, 
Segrate, Italy). Cu concentration in the cell lysates was analyzed by ICP-MS. An aliquot 
of each sample was diluted 1:10  v/v with 5% HNO3 and analyzed with an Agilent 7700 
ICP-MS (Agilent Technologies, Santa Clara, CA, USA) All values of Cu concentration 
were normalized for protein content in corresponding cell lysates. 
 
Microarray Analysis 
To identify the effects of ATP7BH1069Q expression on the transcriptome, total RNA was 
extracted from HepG2 cells (expressing either ATP7BH1069Q-GFP or ATP7BWT-GFP) and 
hybridized on Affymetrix GeneChips. All of the raw microarray data was formatted for 
‘Gene Expression Omnibus’ (GEO) (http://www.ncbi.mln.nih.gov/geo) to comply with 
Minimum Information About a Microarray Experiment (MIAME) and Microarray Gene 
Expression Database (MGED) group standards (GEO number GSE51818). The genes 
differentially expressed in ATP7BH1069Q expressing cells are listed in Supplementary 
Table 1. Microarray analyses were carried out with R, a free software environment 
(available at http://www.r-project.org). After quantification of gene expression with 
robust multi-array normalization (using the BioConductor package affy 
http://www.bioconductor.org) the significance of the differential gene expression was 
determined by computing moderated t-statistic s and false discovery rates with the 
Limma package. Annotation was based on the genome version from the National Center 
for Biotechnology Information. The p values obtained were corrected for multiple testing 
by calculating the estimated false discovery rates using the method of Benjamini-
Hochberg. Basal and luminal genes that passed all of the described filtering criteria 
(including the fold-change cut-off) were entered into the Gene Functional Annotation 
Tool that is available at the Database for Annotation Visualization and Integrated 
Discovery (DAVID) website (http://david.abcc.ncifcrf.gov) using their official gene 
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symbols. The gene ontology options GOTERM_BP_ALL and GOTERM_MF_ALL were 
selected and a functional annotation chart was generated. A maximum p value of 0.05 
was chosen to select only the significant categories. 
 
Luciferase Assay 
HeLa cells were plated in a 12-well plate and transfected with pGL3-E1b-TATA-4MRE 
reporter, empty vector (pEGFP-C1), ATP7BWT-GFP or ATP7BH1069Q-GFP. After 24 
hours, cells were treated with 200 μM CuSO4 for 24 hours. Cells were subsequently 
harvested in a Passive Lysis Buffer (Promega) according to the manufacturer’s 
instructions. Firefly luciferase and Renilla luciferase activities were measured with a 
Dual-Luciferase® reporter assay system (Promega) on a GloMax® 96 Microplate 
Luminometer (Promega) according to the manufacturer’s instructions. Relative Light 
Units were calculated by dividing firefly measurements by Renilla measurements. All 
values were normalized to the ATP7B expression levels in the respective specimens and 
an empty vector was used as a control. 
 
Immuno-electron microscopy. 
For pre-embedding immuno-electron cells microscopy were fixed with mixture of 
4%PFA and 0.05% glutaraldehyde in 0.2 M HEPES for 15 min and with 4%PFA alone 
for 30 min, followed by incubation with blocking/permeabilizing solution: 0.5% bovine 
serum albumin (BSA), 0.1% saponin, 50 mM NH4Cl in PBS for 20-30 min. Primary anti-
GFP antibody and 1.4nm gold-conjugated Fab' fragment of anti-rabbit IgGs were diluted 
in blocking/permeabilizing solution and added to the cells overnight or for 2h 
respectively. GoldEnhance™ EM kit was used to enhance ultrasmall gold particles. Then 
cells were scraped, pelleted, post-fixed in OsO4 and uranyl acetate and embedded in 
Epon. For cryo immuno-electron microscopy HepG2 cells or small 1 mm3 pieces of liver 
tissue from sacrificed mice were rapidly washed in PBS 1X and fixed immediately with a 
mixture of 2% freshly prepared paraformaldehyde and 0.2% glutaraldehyde in 0.1 M 
phosphate buffer for 2 h at room temperature. Before freezing in liquid nitrogen cell and 
tissue gelatin blocks were immersed in 2.3 M sucrose. From each sample, thin plastic or 
cryo sections were cut using Leica EM UC7 or Leica EM FC7 ultramicrotomes 
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respectively (Leica Mycrosystems, Vienna, Austria). Cryo sections were double labeled 
with antibodies against LAMP1 and GFP. EM images were acquired from thin sections 
using a FEI Tecnai-12 electron microscope (FEI, Eindhoven, Netherlands) equipped with 
a VELETTA CCD digital camera (Soft Imaging Systems GmbH, Munster, Germany). 
Morphometric analysis of lysosomal size, distance between lysosomes and PM, 
distribution of ATP7B among different intacellular compartments was performed using 
iTEM software (Olympus SYS, Germany). 
 
Statistical analyses 
Data were expressed as mean values ± standard deviation. Statistical significance (t-test) 
was computed using GraphPad Prism6 software. A p-value <0.05 was considered 
statistically significant. In all figures * means p-value <0.05, ** p-value <0.01, *** p-
value <0.001. 
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